Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
ASX 200 ends the day flat, BOQ (ASX:BOQ) shares drop on impairments
Share Fallers
Why a2 Milk, Bank of Queensland, Mesoblast, & Northern Star are dropping lower today
52-Week Highs
Is the Mesoblast (ASX: MSB) share price still good value?
Share Gainers
Why the Mesoblast (ASX:MSB) share price is surging 8% higher today
Share Market News
5 things to watch on the ASX 200 next week
Share Gainers
Why Mesoblast (ASX:MSB) and this ASX 200 share have doubled in value in 2020
Healthcare Shares
Are biotech shares like Polynovo (ASX:PNV) a better buy than Afterpay?
Share Market News
ASX 200 falls slightly, miners surge higher
Share Market News
The Mesoblast (ASX:MSB) share price surges on award win
Share Gainers
Why Afterpay, Clinuvel, Mesoblast, & Uniti shares are storming higher
⏸️ Shares to Watch
How I'd turn $5,000 into $100,000 with ASX growth shares
Healthcare Shares
Is the Mesoblast share price a bargain yet?
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
